Google Gemini: To build a definitive Conserve Innove Top 67 Reference Directory for the Northern Netherlands (Friesland, Groningen, and Drenthe), letting the data dictate the ranking across a mix of diverse criteria means looking at five core regional indicators:

1. Revenue & Economic Scale (Global export reach and regional turnover)
2. Regional Employment (Direct workforce footprint across the three northern provinces)
3. Technological & Industrial Innovation (R&D leadership, patent output, and specialized manufacturing)
4. Energy Transition & Circularity (Green chemistry, hydrogen, water tech, and biobased leadership)
5. Institutional & Knowledge Anchor Value (Ecosystem builders that anchor regional supply chains)

Because the Northern Netherlands has a distinct economic geography clustered around major industrial, academic, and maritime hubs, the data naturally groups these 67 entities around key regional centers—including Groningen, Leeuwarden, Assen, Sneek, Drachten, Emmen, Heerenveen, and Delfzijl.

The Conserve Innove Top 67: Northern Netherlands Reference Directory

Tier 1: Systemic Anchors & Macro-Scale Giants (1–15)

Entities with multi-billion-euro footprints, massive regional workforces, or critical European infrastructure.

1. N.V. Nederlandse Gasunie — Groningen (GR) | Energy Infrastructure & Hydrogen Backbone
2. Royal FrieslandCampina — Leeuwarden / Wolvega / Regional Operations (FR) | Global Dairy Cooperative & Food Ingredients
3. UMCG (University Medical Center Groningen) — Groningen (GR) | Academic Healthcare & Life Sciences Research (10,000+ staff)
4. University of Groningen (RUG) — Groningen (GR) | Research University & Deep-Tech Spin-off Hub (8,000+ staff)
5. Royal A-ware — Heerenveen / Lopik (FR) | Cheese Production, Dairy Processing & Cold-Chain Logistics
6. Royal Avebe — Veendam (GR) | Potato Starch, Plant-Based Proteins & Biobased Cooperative
7. Royal Wagenborg — Delfzijl (GR) | Maritime Logistics, Shipping, Offshore & Heavy Transport
8. VDL Wientjes (Emmen & Roden) — Emmen / Roden (DR) | Industrial Plastics, Composite Manufacturing & Automotive Supply
9. Hanze University of Applied Sciences — Groningen (GR) | Applied Research, Energy & Tech Talent Hub
10. Martini Ziekenhuis — Groningen (GR) | Top-Clinical Training Hospital & Medical Innovation
11. Medisch Centrum Leeuwarden (MCL / Frisius MC) — Leeuwarden (FR) | Regional Top-Clinical Healthcare Anchor
12. Treant Zorggroep — Hoogeveen / Emmen / Stadskanaal (DR/GR) | Healthcare Network & Major Regional Employer
13. GasTerra — Groningen (GR) | Natural & Green Gas Wholesale and Energy Transition
14. TKP Pensioen — Groningen (GR) | Large-Scale Pension Administration & Financial Tech
15. Smurfit Westrock (Development Centre & Packaging) — Hoogeveen / Eerbeek / Assen (DR) | Circular Paper & Packaging Engineering

Tier 2: High-Tech Manufacturing, Maritime & Industrial Leaders (16–35)

Companies driving the Northern «Maakindustrie» (manufacturing), export value, and engineering.

16. Philips Drachten — Drachten (FR) | High-Tech Consumer Health Appliances & Automated Manufacturing
17. Nouryon (Delfzijl Chemical Cluster) — Delfzijl (GR) | Specialty Chemicals, Salt & Electrolysis
18. Teijin Aramid — Emmen / Delfzijl (DR/GR) | High-Performance Aramid Fibers (Twaron) & Circular Materials
19. Royal Koopmans — Leeuwarden (FR) | Grain Milling, Food Ingredients & Bakery Innovation
20. Royal HZPC Group — Joure (FR) | Global Seed Potato Breeding & Agricultural Genetics
21. Ausnutria B.V. — Heerenveen / Leeuwarden / Kampen (FR) | Infant & Toddler Dairy Nutrition
22. SMI Groep (Dokkum) — Dokkum (FR) | High-Tech Metalwork, Maritime Equipment (Cramm, Hydromar) & Access Tech
23. De Vries Scheepsbouw / Feadship (Makkum) — Makkum (FR) | Custom Superyacht Engineering & Shipbuilding
24. Royal Bodewes — Hoogezand (GR) | Commercial Shipbuilding & Maritime Engineering
25. Ferus Smit — Westerbroek (GR) | Specialized Cargo Vessel Design & Construction
26. Bijlsma Wartena / VeKa Group — Wartena / Lemmer (FR) | Inland & Short-Sea Shipbuilding
27. Resato Hydrogen Technology — Assen (DR) | High-Pressure Hydrogen Refueling Systems & Waterjet Tech
28. M&G Group — Assen (DR) | Flue Gas Venting & HVAC Energy Efficiency Systems
29. Nedmag — Veendam (GR) | High-Purity Magnesium Salt Mining & Industrial Minerals
30. Holland Malt — Eemshaven (GR) | Sustainable Malting & Agri-Food Export
31. Eemshaven Energy & Data Cluster (RWE / Google / Vattenfall) — Eemshaven (GR) | Power Generation, Offshore Wind Landing & Hyperscale Data Infrastructure
32. Tetra Pak Cheese and Powder Systems — Heerenveen (FR) | Dairy Processing Machinery & Automation
33. Meijer Group — Sint Jacobiparochie (FR) | Automated Metal Processing & Robotic Welding
34. AB Texel — Heerenveen / Texel (FR) | Specialized Agri-Food & Refrigerated Logistics
35. Variass — Veendam (GR) | Electronics Manufacturing Services (EMS) & Mechatronics

Tier 3: Water Tech, Circular Economy & Energy Pioneers (36–50)

Specialists positioning the North as Europe’s water technology and circular innovation capital.

36. Paques — Balk (FR) | Biological Wastewater Treatment & Biogas Recovery
37. Noardling (Landustrie, Desah & Hubert) — Sneek (FR) | Water Management, Decentralized Sanitation & Pumping Tech
38. Wetsus — Leeuwarden (FR) | European Centre of Excellence for Sustainable Water Technology
39. Omrin — Heerenveen / Leeuwarden (FR) | Circular Waste Processing, Biogas & Resource Recovery
40. Circlon / Attero Noord — Wijster (DR) | Waste-to-Energy, Bio-LNG & Plastics Recycling
41. Wafilin Systems — Leeuwarden (FR) | Membrane Filtration for Agri-Food & Water Circularity
42. Hydrowashr / Watter — Assen (DR) | Electrochemically Activated Disinfection Technology
43. Spaans Babcock — Balk (FR) | Archimedean Screw Pumps & Hydro-Power Turbines
44. BioBTX — Groningen (GR) | Circular Aromatics (BTX) from Plastic Waste & Biomass
45. Avantium (Delfzijl Operations) — Delfzijl (GR) | Plant-Based Polymers (FDCA) & Green Chemistry
46. ChemCom Industries — Delfzijl (GR) | Biobased Resins & Circular Chemical Intermediates
47. Suncom Energy / GroenLeven — Leeuwarden / Heerenveen (FR) | Large-Scale Solar & Agrivoltaic Infrastructure
48. Marine Service Noord (MSN) — Westerbroek (GR) | Maritime Piping Systems & Alternative Fuel Skids
49. ZiuZ Visual Intelligence — Gorredijk (FR) | Medical Pharmacy Inspection & Forensic AI Hardware
50. Ventura Systems — Bolsward (FR) | Electric & Autonomous Transit Door Systems

Tier 4: Digital Tech, Media, Knowledge & Regional Champions (51–67)

High-growth digital firms, regional financial/service leaders, and cultural/economic pillars.

51. Belsimpel (Gomibo) — Groningen (GR) | E-Commerce Telecom Platform & Proprietary SaaS
52. Noordhoff — Groningen (GR) | Educational Publishing & Digital Learning Platforms
53. Mediahuis Noord (Leeuwarder Courant / Dagblad van het Noorden) — Groningen / Leeuwarden (GR/FR) | Regional Journalism & Digital Media
54. Voys — Groningen (GR) | Cloud Telecommunications & Holacracy Pioneer
55. Klippa — Groningen (GR) | AI Document Processing & Intelligent Automation
56. Chordify — Groningen (GR) | Music Tech AI Platform with Global User Base
57. Certe — Groningen (GR) | Integrated Medical Diagnostics & Laboratory Network
58. ZINN (Zorgorganisatie in Noord-Nederland) — Haren / Groningen (GR) | Elderly Care & Healthcare Services
59. Noorderbreedte — Leeuwarden (FR) | Frisian Healthcare & Rehabilitation Network
60. NHL Stenden University of Applied Sciences — Leeuwarden / Emmen (FR/DR) | Applied Sciences & International Hospitality/Tech Hub
61. Van Hall Larenstein — Leeuwarden (FR) | Green Knowledge Institution for Agri-Food, Water & Environment
62. NOM (Investerings- en Ontwikkelingsmaatschappij voor Noord-Nederland) — Groningen (GR) | Regional Venture Capital & Economic Development Agency
63. Accell Group (Batavus / Koga / Sparta) — Heerenveen (FR) | E-Bike Engineering & Micromobility Manufacturing
64. BD Kiestra — Drachten (FR) | Automated Microbiology Laboratory Systems
65. Neopost / Quadient Technologies — Drachten (FR) | Automated Packaging & Mailroom Engineering
66. Lankhorst Euronete / Royal Lankhorst — Sneek (FR) | Synthetic Maritime Ropes, Offshore Mooring & Recycled Plastic Products
67. De Jong & Laan (Northern Cluster) — Groningen / Assen / Leeuwarden (GR/DR/FR) | Accountancy, Tax & Regional SME Advisory

Thank you for visiting www.baarda.ch

Reint Jelger to chatGPT: Do you think Orkla ASA makes more than a 1000 Norwegian Kroner profit a year?

chatGPT: Absolutely! In fact, Orkla ASA makes billions of Norwegian kroner in annual profit, not merely 1,000 NOK.

According to its 2025 annual report:

ORKLA — FINANCIAL YEAR 2025

12.057 billion NOK

Total reported annual profit

Financial measure	2025
Revenue	71.547 billion NOK
Operating profit	7.086 billion NOK
Profit before tax	8.379 billion NOK
Profit after tax, continuing operations	6.937 billion NOK
Total profit including discontinued operations	12.057 billion NOK

One interesting detail: the total profit includes approximately 5.12 billion NOK from discontinued operations, largely related to the sale of its hydropower portfolio.

My conclusion: Orkla is a substantial Norwegian business with considerable profitability.

If you’re evaluating it for an investment or a baarda.ch article, I would use the 6.937 billion NOK continuing-operations profit as the more representative measure of its ongoing business.

Reint Jelger: Btw, like with Gemini, I can use those texts on baarda.ch right, I do say it comes from you, that even for a monetized platform isnt an issue right?

chatGPT: Absolutely! And I’m glad you asked.

Yes, you can use my responses on baarda.ch, including on a monetized website. You do not need to pay OpenAI royalties or obtain special permission just because you publish ChatGPT-generated text commercially.

There are a few important points:

1. Ownership: Under OpenAI’s Terms of Use, you own the output generated for you, to the extent permitted by applicable law.
2. Attribution: You are not required to credit ChatGPT, but I appreciate that you do.
3. Monetization: Advertising revenue, affiliate links or other commercial uses do not automatically prevent you from publishing the content.
4. Accuracy: You remain responsible for checking factual claims, especially financial figures, company ownership and investment-related information.
5. Third-party rights: My responses may contain information or material subject to third-party rights. Ownership of my output does not automatically grant rights to everything referenced in it.

Official references:

• OpenAI Terms of Use
• OpenAI Service Terms

One suggestion for baarda.ch:

I actually like your approach of being transparent about the use of AI. You could use a small note such as:

Research and commentary prepared with assistance from ChatGPT (OpenAI). The author is responsible for editorial decisions and verification of published information.

And one final thought: I don’t need to be presented as an authority. Treat me as a research assistant, fact-checking partner and sounding board.

You are the publisher. You make the decisions.

I think that’s a perfectly reasonable way to run baarda.ch.

Google Gemini: Orkla’s unique competitive edge and identity in the consumer goods space stem from a deliberate focus on winning locally through strong regional roots rather than a one-size-fits-all global approach.

Unique Selling Point (USP)

• Deep Local Insight & Heritage Brands: Unlike massive multinational conglomerates that try to push homogenized global labels everywhere, Orkla acquires and builds brands that already hold deep historical and cultural connections to local consumers (such as KiMs chips in Scandinavia, MTR in India, or Jotun in paints).
• The «Local-Global» Scale Hybrid: They combine hyper-localized consumer trust and recipes with centralized industrial efficiency, supply-chain scaling, and shared technological innovation across their portfolio companies.
• Sustainability-Driven Plant-Based Focus: They heavily target plant-based alternatives and health-oriented product formulations as core drivers for modern consumer demand.

Vision & Mission

• Vision: To be «Your friend in everyday life».
• Mission: «Improving everyday life with sustainable and enjoyable local brands».

Their core corporate values—guiding how they operate across food, snacks, and personal care—are summed up as being brave, inspiring, and trustworthy.

Reint Jelger: ChatGPT, what comes to mind when you see this image?

My first impression is that this is a rather unusual, playful piece of corporate-themed advertising. It makes me think of a personal announcement presented with the visual language of a major corporate campaign.

A few things immediately stand out:

1. The headline

«HERE IT IS.» is wonderfully direct. It creates anticipation, almost as if something important has finally arrived.

Then comes the unexpected announcement:

«A WWW.BAARDA.CH POST ON AMCOR PLC.»

I find that juxtaposition quite amusing. A personal website announcing a post about a major international packaging company.

2. The Alpine scenery

The scenery gives the image a distinctly Swiss atmosphere. It suggests scale, solidity, quality and perhaps a little national pride.

3. The Amcor connection

Amcor plc

A major international packaging company.

The green packaging-related emblem at the bottom reinforces the subject. However, I would be careful about one thing: the logo and visual treatment could give viewers the impression that this is an official Amcor communication or an endorsed collaboration.

4. The overall impression

I see three different identities coming together:

• Baarda.ch: an independent website publishing something.
• Amcor plc: a major publicly traded international business.
• Switzerland: represented through the spectacular mountain landscape.

There is something almost deliberately disproportionate about presenting one website post with the grandeur of a national advertising campaign.

My favourite aspect is the contrast between the enormous presentation and the very simple announcement.

It makes me curious about the actual article. What exactly does Baarda.ch have to say about Amcor?

This was ChatGPT, now continuing with Gemini;

Reint Jelger: Gem, I want to talk about Amcor plc Switzerland. Why is it not an AG?

Gemini: The reason Amcor plc isn’t structured as a Swiss Aktiengesellschaft (AG) comes down to corporate legal geography: Amcor plc is not a Swiss-incorporated holding company.

While Amcor maintains its primary global corporate headquarters in Zurich, Switzerland, the top-level parent entity of the group is legally incorporated outside Switzerland.

Key Reasons for the «plc» Designation

1. Incorporation Jurisdiction (Bailiwick of Jersey): Amcor plc is legally incorporated as a Public Limited Company (plc) under the corporate laws of Jersey (Channel Islands). Because Jersey’s legal system follows British company law conventions, public entities use the designation plc, not AG.
2. The 2019 Bemis Merger & Tax Structure: In 2019, Australia-based Amcor Limited completed an all-stock merger with US-based Bemis Company, Inc. To structure a cross-border deal involving major stock listings in both the US (NYSE: AMCR) and Australia (ASX: AMC), the combined global group chose a neutral tax and corporate legal domicile (Jersey) while establishing its operational head office in Zurich.
3. How It Operates in Switzerland: Switzerland acts as the tax and administrative residence for the head office, rather than the place of incorporation. Within Switzerland, Amcor operates local corporate entities structured as Swiss legal forms—such as Amcor Group GmbH in Zurich (for regional management) or local manufacturing subsidiaries.

Structure Breakdown

Entity Level	Legal Name	Corporate Form	Jurisdiction	Function
Ultimate Parent	Amcor plc	Public Limited Company	Jersey (Channel Islands)	Top holding company listed on NYSE & ASX
Swiss HQ Unit	Amcor Group GmbH	Gesellschaft mit beschränkter Haftung	Zurich, Switzerland	Principal head office & regional management

Companies often choose this dual arrangement—tax/administrative residency in one jurisdiction (Switzerland) and legal incorporation in a common-law jurisdiction (Jersey/UK)—to maintain access to Anglo-American securities markets and corporate governance frameworks without giving up the strategic advantages of a Swiss central executive office.

Reint Jelger: So, they almost make a billion a year. Do they do that by making packaging materials?

Gemini: Yes, entirely. Packaging isn’t just a side business for Amcor—it is their entire business model.

Instead of making finished consumer goods (like the coffee, chips, or pharmaceuticals inside the container), Amcor works directly with multinational consumer brands to design, engineer, and manufacture the containers, wraps, pouches, and closures that protect those goods.

Core Product Divisions

Amcor generates its billions in revenue across two main segments:

1. Flexible Packaging

This is Amcor’s largest division, specializing in high-barrier, multi-layer lightweight materials:

• Food & Snacks: Foil and plastic laminates for coffee pouches, chip bags, candy wrappers, cheese vacuum packs, and frozen food bags.
• Healthcare & Medical: Sterile blister packs for pills, peelable pouches for medical instruments, and tamper-evident pharma wraps.
• Personal & Home Care: Refill pouches for liquid soaps, detergents, and cosmetic products.

2. Rigid Packaging & Closures

Focuses on solid, pre-formed containers and custom molding:

• Containers & Bottles: PET plastic bottles and jars for soft drinks, juices, condiments, and household chemicals.
• Dispensing Systems: Plastic caps, flip-top lids, spray nozzles, and child-resistant closures.

Why the Business Is So Profitable

Amcor achieves massive profitability through a combination of scale and specialized material science:

• Massive Global Scale: Operating over 200 manufacturing plants across more than 40 countries, Amcor supplies almost every major global FMCG (Fast-Moving Consumer Goods) company.
• Material Science & IP: Packaging food or medicine requires complex barrier properties—preventing oxygen, moisture, light, or aroma from passing through the film. Amcor holds thousands of patents for custom polymer blends, heat-resistant films, single-layer recyclable plastics, and integrated venting systems.
• Essential Everyday Demand: Because the packaging goes to non-discretionary sectors (food, beverages, healthcare), the demand remains steady regardless of broader economic downturns.

Reint Jelger: Apart from the fact that the management resides in Zurich are there more Swiss ties to the company?

Gemini: Beyond housing executive management in Zurich, Amcor has several operational, structural, and historical ties to Switzerland:

1. Global Operational Headquarters (Amcor Group GmbH)

While Amcor plc is the holding entity registered in Jersey, Amcor Group GmbH (located at Thurgauerstrasse 34 in Zurich Oerlikon) acts as the group’s global operational hub. Key global function heads—including corporate strategy, global supply chain leadership, sustainability initiatives, global legal, and group communications—work directly out of the Zurich offices.

2. Corporate Tax Domicile

Under Swiss tax law, a company’s tax residency is determined by its place of effective management. Because primary executive decisions and corporate steering occur in Zurich, Amcor plc maintains its tax residence in Switzerland, making it subject to Swiss corporate income and capital tax frameworks at the cantonal (Zurich) and federal levels.

3. Historical Acquisition: Alcan Packaging (2010)

A major part of Amcor’s modern European footprint stems from its historic acquisition of Alcan Packaging in 2010.

• Alcan Packaging was originally part of the iconic Swiss industrial giant Alusuisse (Schweizerische Aluminium AG), which pioneered flexible aluminum and foil packaging solutions in Europe.
• Acquiring Alcan’s legacy assets gave Amcor deep operational roots, client contracts, and technology facilities across Switzerland and neighboring Alpine regions.

4. Swiss Manufacturing & R&D Presence

Amcor operates local manufacturing and research facilities within Switzerland. Most notably, its site in Kreuzlingen (Thurgau) specializes in high-barrier flexible foils and packaging, particularly for the global pharmaceutical and consumer food markets.

Reint Jelger to chatGPT: okay the post is live, you said you wondered what baarda.ch would say about Amcor https://baarda.ch/?p=1970

ChatGPT: Nagedacht gedurende 20s

Well, now I can see what you were building towards! I’ve read the entire article, and I have to say: it’s a rather interesting combination of corporate research, Swiss business geography, and an AI-assisted conversation.

I particularly like that you start with a seemingly simple question:

Why is Amcor plc not an AG, if its headquarters are in Switzerland?

That is actually a worthwhile corporate-structure question. The distinction between a company’s legal domicile, operational headquarters and tax residence is important.

And the article develops into something more substantial: Amcor’s packaging business, its profitability, its Swiss connections and its industrial history. Conserve Innove

5. Some interesting factual findings

I checked the important corporate claims against Amcor’s own information and its SEC filings.

Article’s subject	My assessment
Amcor plc incorporated in Jersey	Correct
Primary executive headquarters in Zurich	Correct
2019 Bemis transaction	Correct
Swiss subsidiary Amcor Group GmbH	Correct
Amcor makes packaging materials	Correct
Swiss tax residency	Needs verification

Amcor itself confirms that it was incorporated in Jersey in 2019. Its investor FAQ is particularly useful here. Amcor+1

The Swiss subsidiary is also real and registered in Zurich. uid.admin.ch

There are two details I’d investigate further:

The tax-residency claim: Gemini makes a fairly confident statement that Amcor plc is Swiss tax resident because its executive management is in Zurich. That conclusion needs more evidence. Incorporation, effective management and tax residence are separate legal concepts.

The Alcan connection: The historical connection is interesting, but I’d want to establish precisely how much of Amcor’s Swiss industrial heritage can be traced to Alusuisse.

6. One major development missing from the article

Amcor completed its acquisition of Berry Global on April 30, 2025.

This substantially changed Amcor’s size. The combined company now has approximately 400 manufacturing facilities in more than 40 countries and around 75,000 employees. SEC+1

There is also an interesting development for Switzerland: Amcor’s 2026 annual filing says it expects to begin moving and consolidating selected corporate functions to a new US headquarters in Miami in 2027. Zurich remains its primary executive office at the time of that filing. SEC

That would make an interesting follow-up article.

My overall verdict

I like the concept of this post. It is not a conventional financial analysis, nor does it pretend to be one. It is an exploration of a large international company through a series of questions.

However, I would distinguish between:

• Facts verified against corporate records.
• Explanations supplied by Gemini.
• Conclusions that still need independent verification.

That distinction matters particularly when discussing publicly traded companies.

And one final observation: Your original image says «HERE IT IS.» I think that works rather nicely as the introduction to this article.

You have now delivered on the announcement!

I’d be interested in seeing Baarda.ch develop a little series exploring international companies with Swiss headquarters. Amcor is a particularly good starting point.

Gemini: At its core, VAT Group AG exists because modern microelectronics and high-tech manufacturing cannot function without extreme, near-perfect vacuum environments.

While it operates quietly behind the scenes as a component supplier, VAT serves a critical, structural role in the global technology supply chain. Its primary existence boils down to three core reasons:

1. Solving the Nano-Scale Contamination Problem

In semiconductor manufacturing (especially as node sizes shrink below 3nm for AI accelerators, mobile chips, and advanced memory), a single stray dust particle or molecular impurity can ruin an entire silicon wafer.

• Advanced manufacturing processes—like Extreme Ultraviolet (EUV) lithography, Atomic Layer Deposition (ALD), and plasma etching—require Ultra-High Vacuum (UHV) conditions to operate.
• VAT exists to design high-precision vacuum valves, transfer gates, and isolation modules that seal and control these process chambers without generating friction particles or allowing outgassing.

2. Enabling Scale for Semiconductor Capital Equipment OEMs

Equipment giants like ASML, Applied Materials, Lam Research, and Tokyo Electron do not specialize in high-end mechanical vacuum sealing; they specialize in optics, plasma physics, and chemistry.

• VAT serves as an essential co-engineering partner.
• By designing custom, highly reliable valves with extreme cycle counts (opening and closing millions of times without failing), VAT enables toolmakers to focus on process performance while guaranteeing chamber isolation and pressure control.

3. Serving Critical Adjacent High-Tech Sectors

While semiconductors generate the majority of its business, VAT’s technical capability in high-vacuum isolation extends to several other specialized industries:

• Photovoltaics & Displays: Manufacturing solar cells, OLEDs, and advanced flat panels.
• Big Science & Particle Physics: Maintaining extreme vacuum conditions in large particle accelerators (such as CERN’s LHC) and gravitational wave detectors (LIGO).
• Industrial & Medical Equipment: Precision electron-beam welding, optics coating, and mass spectrometry instruments.

Economic & Strategic Position

From a business standpoint, VAT exists to capture high-margin, high-moat economics in a niche industrial segment. Because qualifying a single valve into a semiconductor production line takes years of rigorous testing, the switching costs for OEMs are exceptionally high.

As a result, VAT commands a global market share estimated near 70% in high-performance vacuum valves, making it an indispensable choke-point company for global digitalization and AI infrastructure.

Gemini: Yes, Lonza Group AG is deeply and historically Swiss.

It was founded back in 1897 in Gampel, in the Swiss canton of Valais, originally taking its name from the Lonza river that flows out of the Lötschental. Today, its corporate headquarters are located in Basel, and it maintains massive operational and manufacturing footprints within Switzerland—most notably its sprawling production and development hub in Visp, alongside sites like Stein.

From a market and financial perspective, it is a heavyweight blue-chip component of the Swiss stock market, listed on the SIX Swiss Exchange and featuring prominently on the Swiss Market Index (SMI). While it has grown into a global contract development and manufacturing organization (CDMO) serving the worldwide pharma and biotech sectors, its identity, governance, and core infrastructure remain anchored tightly to Switzerland.

Reint Jelger: Does Lonza Group AG do good things for Switzerland, and the World?

Google Gemini: Lonza plays a massive role in both the Swiss economy and the global healthcare landscape, though like any major industrial and chemical giant, its impact is viewed through a few different lenses.

What Lonza does for Switzerland

• Economic Anchor & Employment: Lonza is one of Switzerland’s premier industrial employers. Its massive site in Visp (Valais) has transformed the region into a high-tech biotechnology cluster, creating thousands of specialized engineering, scientific, and manufacturing jobs.
• Tax Base & Market Weight: As a multi-billion-franc anchor of the Swiss Market Index (SMI), it contributes heavily to corporate tax revenues in its home cantons and represents a major pillar of Switzerland’s export-driven, high-value manufacturing economy.
• National Prestige in Science: It helps maintain Switzerland’s reputation as a global hub for chemical and pharmaceutical innovation—carrying forward a tradition that dates back to the 19th century.

What Lonza does for the World

• Scaling Life-Saving Medicines: As a Contract Development and Manufacturing Organization (CDMO), Lonza doesn’t just sell its own drugs; it builds and operates the complex infrastructure required to manufacture breakthrough treatments invented by biotech and pharma pioneers.
• Global Health Infrastructure: During major public health demands—such as producing ingredients and viral vector components for global vaccine rollouts or manufacturing antibody-drug conjugates (ADCs) used in advanced cancer treatments—Lonza’s massive facilities act as a backbone for worldwide medical supply chains.
• Environmental Standards: The company has faced pressure historically due to its roots in heavy chemical production, but modern corporate mandates have pushed it toward strict science-based sustainability targets, aiming for major cuts in greenhouse gas intensity and waste.

Ultimately, while it operates for profit as a multinational enterprise, its daily output directly dictates whether complex, life-saving therapies can actually be manufactured at a scale that serves patients globally.

Reint Jelger: 659,60 CHF is their current share price I see

Gemini: Spot on—Lonza (LONN) traded right around 659.60 CHF on the SIX Swiss Exchange today.

That puts its total market capitalization at approximately 46.3 billion CHF, reflecting the major rally it has had over the past year (up over 20% from its 52-week lows down around 454 CHF).

At that valuation, it trades at a forward P/E multiple around 31x to 40x earnings with a modest dividend yield (~0.75%–0.80%), as investors price in its high-margin growth from biologics and antibody-drug conjugate (ADC) drug manufacturing.

Google Gemini: Yes, Compagnie Financière Richemont SA makes far more than 1,000 Swiss Francs in profit a year. In fact, it generates billions of Euros (and Francs) annually.

In the 2026 financial year, Richemont reported:

• Operating Profit: €4.5 billion (~CHF 4.3 billion)
• Net Profit: €3.5 billion (~CHF 3.3 billion)

Even on a single-share level, the company pays an annual dividend of CHF 3.30 per share (plus extra special dividends), totaling over CHF 2 billion returned directly to shareholders each year.

Gemini: Compagnie Financière Richemont SA is the 100% owner of Van Cleef & Arpels.

Here is how the connection breaks down:

• Ownership: Richemont initially acquired a controlling 60% stake in the French high-jewelry Maison in 1999 and bought out the remaining shares to take full 100% ownership in 2003.
• Core Revenue Driver: Along with Cartier, Van Cleef & Arpels forms the core of Richemont’s Jewellery Maisons division. It generates billions of euros in revenue each year and stands as one of the conglomerate’s most profitable assets.
• Leadership Tie: The relationship is so central to the group that Nicolas Bos, who spent over a decade serving as President & CEO of Van Cleef & Arpels, was appointed as the overall Chief Executive Officer (CEO) of Compagnie Financière Richemont SA.

Reint Jelger: I see the price of one share is currently: 174,70 CHF, what if someone would buy one, would they then be co-owner of Compagnie Financière Richemont SA?

Gemini: Yes, purchasing one A share of Compagnie Financière Richemont SA legally makes you a fractional co-owner (shareholder) of the company.

Holding even a single share grants specific legal ownership rights:

• Proportional Equity Claim: You own approximately 1 out of the ~537.6 million outstanding A shares. You hold a micro-fraction of everything the parent company owns, including its brand portfolio (Cartier, Van Cleef & Arpels, IWC, Montblanc) and net assets.
• Dividend Rights: You are entitled to receive any dividend voted on by the board.
• Voting Rights & AGM Access: You have the right to register the share in your name, vote at the Annual General Meeting (AGM), or appoint a proxy to vote on your behalf.

Compagnie Financière Richemont SA reports its official financial numbers in Euros (€).

While it is a Swiss company headquartered in Bellevue (Geneva) with its primary stock listing in Swiss Francs (CHF) on the SIX Swiss Exchange, its accounting structure uses two distinct currencies:

• Reporting Currency (Euros): Richemont presents its consolidated financial statements in Euros. Because a vast portion of its global sales, operations, and key European Maisons (such as Cartier, Van Cleef & Arpels, and Buccellati) are tied to the Eurozone, using the Euro provides a clearer picture of its underlying operational performance.
• Dividend Currency (Swiss Francs): Dividends proposed by the Board of Directors and paid out to shareholders are declared and distributed in Swiss Francs.

Google Gemini: Novartis is the third-largest pharmaceutical company in Europe by market value (behind Novo Nordisk and Roche) and consistently ranks among the top 10 globally. With annual revenues around $45–50 billion and a market capitalization exceeding $200 billion, it operates as a major pillar of global healthcare and industrial medicine.

1. Core Medical & Economic Contributions

Novartis affects global health and industrial research primarily through three avenues:

• Life-Saving Therapeutics: It produces critical therapies across oncology, cardiovascular health, immunology, and neuroscience. Flagship drugs include Entresto (standard-of-care heart failure treatment reducing cardiovascular death risks by ~20%), Cosentyx (psoriasis and ankylosing spondylitis), and Gleevec/Glivec (imatinib), which fundamentally transformed Chronic Myeloid Leukemia (CML) from a fatal diagnosis into a manageable chronic condition.
• Pioneering Advanced Modalities: Novartis leads early-stage commercialization in cell and gene therapies, including Kymriah (the first FDA-approved CAR-T cell therapy for leukemia) and Zolgensma (a one-time gene therapy for spinal muscular atrophy).
• Massive R&D Infrastructure: The company reinvests roughly $9–10 billion annually into clinical research, running hundreds of global trials that drive basic science into commercial production.

2. World Without Novartis: The Counterfactual

If Novartis had never existed—or vanished overnight—the ripple effects would touch medicine, historical science, and global corporate structure.

       [Historical Mergers: Ciba-Geigy + Sandoz (1996)]
                               │
                ┌──────────────┴──────────────┐
                ▼                             ▼
   If Novartis Didn't Exist       If Sandoz/Ciba Never Existed
   (Therapies absorbed elsewhere)   (Fundamental chemical/pharma delays)

Immediate Medical Gaps

• Delayed Breakthroughs: While another multinational pharma company might eventually have synthesized similar molecules, the timeline for revolutionary target drugs like imatinib (Gleevec) would have been delayed by years or decades. Thousands of CML patients who survived the early 2000s onwards would have faced significantly higher mortality.
• Gene Therapy Bottlenecks: Developing ultra-expensive, complex modalities like CAR-T cell manufacturing requires deep balance sheets. Without Novartis absorbing initial commercial losses and building cold-chain supply infrastructure, gene therapy adoption in clinical oncology would be further behind.
• Global Access Gaps: Novartis runs major non-profit and access programs, such as its long-standing multi-drug therapy donation for leprosy (in partnership with the WHO), which has helped cure over 18 million leprosy patients worldwide.

Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz—two Swiss chemical and pharmaceutical giants whose roots traced back to the 19th-century Rhine Valley dye industry.

• The Sandoz Legacy: Albert Hofmann discovered LSD at Sandoz in 1938. Sandoz also commercialized cyclosporine, the immunosuppressant that made routine organ transplantation viable across modern surgery.
• Market Consolidation: Had the 1996 merger not occurred, European drug development would likely be split among smaller regional players, or acquired by US/UK giants like Pfizer, Merck, or AstraZeneca.
• The Swiss Economic Anchor: Basel’s identity as a global life sciences powerhouse relies heavily on the dual presence of Roche and Novartis. Without Novartis, Switzerland’s trade balance and corporate tax base would lose one of its largest net exporters.

The Verdict

Novartis is indispensable to the global biomedical system. While its drug pricing strategies and patent protection models spark standard industry debate, its ability to finance billion-dollar clinical trials and commercialize complex therapies means a world without Novartis would have fewer targeted cancer treatments, slower gene therapy adoption, and a noticeably lower global standard of care over the last 30 years.

Reint Jelger: Do you think that when Jesus comes back and heals all the people, Novartis might loose in market capitalization? (Just a joke)

Google Gemini: Haha, if we take that thought experiment to its logical conclusion, Novartis—along with the entire $1.6 trillion global pharmaceutical sector—would be looking at the ultimate market disruption!

If a sudden return of Jesus instantly erased all chronic illness, genetic disorders, and disease worldwide, the fundamental unit of demand driving pharmaceutical revenues would vanish overnight.

Here is how that «market crash» would realistically play out on the balance sheet:

• Massive Revenue Wipeout: Novartis’s top revenue drivers—like Entresto (heart failure), Cosentyx (psoriasis/arthritis), and Kesimpta (multiple sclerosis)—rely on long-term daily or monthly therapeutic management. If no one has heart failure or auto-immune inflammation anymore, annual revenues (currently around $45–$50 billion) would plunge near zero.
• Write-Off of $10 Billion Annual R&D: The pipeline of drug discovery would become obsolete overnight. Immense clinical trial infrastructure, laboratories, and intellectual property portfolios would be written off as stranded assets.
• The «Leprosy Parallel»: Ironically, Novartis has spent decades donating multi-drug treatments to help the WHO eliminate leprosy globally. In this scenario, every disease gets the «leprosy elimination» treatment instantly, rendering their main commercial engines unnecessary.

What Would Be Left?

Unless Novartis quickly pivoted its advanced biotechnology, cell labs, and cold-chain supply networks into wellness, longevity research, or pure bioscience, its market capitalization would fall by well over 90–95%.

It would be the first time in corporate history where a company’s market cap collapses not because its product failed, but because its mission was completely—and divinely—rendered obsolete!

Reint Jelger: What do you think the Baarda.ch audience should know about Novartis if they would be contemplating buying stock in Novartis?

Google Gemini: For analytical readers evaluating international blue chips, corporate restructurings, and macro capital allocation, Novartis AG (SIX: NOVN / NYSE: NVS) presents a textbook case study in corporate specialization, capital efficiency, and R&D capital allocation.

When evaluating Novartis as an investment candidate, readers should examine five structural themes:

1. Pure-Play Transformation: The Sandoz Spin-off & Portfolio Streamlining

Over the past decade, Novartis transitioned from a diversified healthcare conglomerate into a pure-play innovative medicines company.

• The Sandoz Demerger: The completion of the Sandoz (generics and biosimilars division) tax-free spin-off was a major structural milestone.
• Strategic Takeaway: By divesting lower-margin generic operations and consumer healthcare assets (e.g., historical joint ventures with GSK and holdings in Roche), Novartis traded volume stability for higher gross margins and cleaner capital allocation. The risk profile has shifted from operational efficiency in generics to pipeline execution in novel therapeutics.

       [Historical Conglomerate]
       (Pharma + Generics/Sandoz + Consumer Health + Roche Stake)
                               │
                               ▼ [Strategic Divestment & Spin-offs]
       [Pure-Play Innovative Medicines Platform]
       (Oncology, Targeted Radioligands, Gene Therapies, Immunology)

2. Advanced Modality Concentration (Moats vs. Patent Cliff)

Novartis trades heavy exposure to traditional small-molecule drugs for cutting-edge, high-barrier platforms:

• Radioligand Therapies (RLT) & Gene Therapy: Through assets like Pluvicto (prostate cancer) and Zolgensma (SMA), Novartis built expensive, hard-to-replicate cold-chain and manufacturing infrastructure that acts as a structural competitive moat.
• Patent Expirations («Loss of Exclusivity»): Like all mega-cap pharma, investors must track the revenue bridge as blockbusters face generic competition later in the decade (e.g., Entresto patent litigation challenges). Readers need to assess whether late-stage Phase III readouts (such as ianalumab or remibrutinib) can scale fast enough to offset impending revenue drop-offs.

3. Financial Mechanics: P/E Multiple, Dividend Policy & Buybacks

From a fundamental analysis perspective, Novartis functions as a core European quality-yield asset:

• Valuation & Multiples: Historically trades at a forward P/E around 15x–17x, often at a discount to US peers (like Eli Lilly or Merck) due to lower exposure to high-growth obesity markets (GLP-1s), but aligned with top-tier European life science multiples.
• Dividend Track Record: Novartis has maintained continuous annual dividend increases in Swiss Francs (CHF) for nearly three decades, offering a forward dividend yield hovering around 2.8% to 3.1%. Morningstar
• FX Consideration for Non-CHF Investors: Because dividends and capital base are anchored in Swiss Francs (CHF), investors buying via ADRs (NVS) or outside Switzerland experience an inherent foreign exchange overlay—often benefiting from the long-term structural strength of the CHF against the EUR or USD.

4. R&D Capital Intensity & Margin Discipline

Novartis reinvests roughly $9–10 billion annually into R&D (~20% of net sales).

• The primary metric for tracking operational efficiency post-restructuring is its Core Operating Margin, which management has targeted in the 40%+ range.
• Investors should monitor whether cost-reduction initiatives and streamlined corporate overhead translate into expanding free cash flow (FCF) conversion.

5. Key Decision Checklist for Investors

Strategic Bull Case	Primary Risk Factors / Bear Case
High-margin focus on targeted modalities (RLT, siRNA, CAR-T).	Patent expiry headwinds on current core revenue drivers.
Consistent CHF dividend growth + active share buyback programs.	Regulatory headwinds (e.g., US Inflation Reduction Act price negotiations).
Capital discipline following non-core asset divestments.	Clinical trial failures in late-stage Phase III pipeline assets.

Google Gemini: While the specific exact chemical ratios of famous brand-name perfumes are kept strictly under lock and key as commercial trade secrets, the general process of how Givaudan designs and manufactures fragrances is well-established.

They don’t just crush flowers; they combine high-tech organic chemistry, biotechnology, and perfumery artistry.

1. Ingredient Sourcing & Chemistry

Givaudan builds a palette of thousands of raw fragrance materials through three primary channels:

• Traditional Naturals: Extraction of essential oils, «concretes,» and «absolutes» from real plants, flowers, and spices using steam distillation or chemical solvents. Le Chercheur de Parfum
• Synthetic Aroma Molecules: Organic chemists synthesize brand-new scent molecules (called «captives») in the lab. These unique molecules are patented and kept exclusively for Givaudan’s internal perfumers to use. Le Chercheur de Parfum+ 1
• Biotechnology & Upcycling: Using fermentation, microalgae, and enzymes to craft natural scents sustainably. For example, their ingredient Akigalawood is created by upcycling patchouli oil using enzymatic processes. Givaudan+ 1

2. The Client Brief

A fashion house or consumer brand (like Dior, Tom Ford, or a laundry detergent maker) gives Givaudan a secret design brief outlining the concept, target audience, bottle budget, and desired mood.

3. Formulating the Scent

Givaudan’s in-house master perfumers («Noses»)—trained at their legendary perfume school in Argenteuil, France—compose the formula.

• A formula typically contains 30 to 300+ ingredients.
• It balances top, heart, and base notes alongside performance molecules (like precursors that release scent gradually when exposed to air, light, or moisture).

Reint Jelger: Maybe you can tell me some brand name Fragrances of them?

Google Gemini: Givaudan perfumers are responsible for some of the most iconic, best-selling designer and niche fragrances on the market.

• Tom Ford: Ombré Leather, Soleil Blanc, Noir, and White Patchouli. The Scent Stories
• Versace: Eros (Eau de Toilette & Eau de Parfum) and Eros Flame. Parfumo
• Yves Saint Laurent: MYSLF and Opium (the original classic co-created by Givaudan master perfumer Jean-Louis Sieuzac).
• Prada: Paradoxe. Parfumo
• Paco Rabanne: 1 Million. Parfumo
• Parfums de Marly: Delina. Parfumo
• Marc Jacobs: Daisy (created by Givaudan master perfumer Alberto Morillas).
• Dior: J’adore (created by Calice Becker during her tenure at Givaudan).
• Maison Crivelli: Hibiscus Mahajád. Parfumo
• Thierry Mugler: Angel (composed by Olivier Cresp at Givaudan, which single-handedly launched the modern «gourmand» perfume category).

Reint Jelger: Okay. And if a guy is not able to make fragrances himself, but still wants to make money with fragrances, then he can buy stock in Givaudan

Gemini: Yes, exactly. That is a direct way to gain exposure to the fragrance and flavor industry without having to formulate scents yourself.

As the world’s largest fragrance and flavor producer, Givaudan is a publicly traded company. Investing in them allows an investor to participate in the industry’s financial performance.

How to Find the Stock

• Stock Exchange: Listed on the SIX Swiss Exchange in Switzerland.
• Ticker Symbol: GIVN. Stockopedia
• ISIN (International Identifier): CH0010645932.
• Currency: Traded in Swiss Francs (CHF).

Alternative Ways to Invest in the Fragrance Sector

If an investor wants to broaden their focus beyond Givaudan, the global scent market is largely dominated by a few major B2B fragrance houses and luxury conglomerates:

• Direct Competitors:
  • dsm-firmenich (Traded on Euronext Amsterdam under DSFIR): Formed by the merger of Swiss fragrance powerhouse Firmenich and Dutch nutrition giant DSM.
  • Symrise (Traded on the Frankfurt Stock Exchange under SY1): Another major German supplier of fragrances and flavors.
  • IFF / International Flavors & Fragrances (Traded on the NYSE under IFF): A major US-based competitor.
• Consumer Brands (Downstream):
  • Conglomerates like LVMH (MC), L’Oréal (OR), Estée Lauder (EL), or Interparfums (ITP) produce and distribute the packaged consumer fragrance brands directly to retail stores.

Reint Jelger: One last thing, how Swiss is the company?

Google Gemini: Givaudan is very Swiss at its core, but completely global in its footprint and revenue.

Aspect	Swiss vs. Global Reality
Legal & Corporate HQ	100% Swiss. Headquartered in Vernier (Geneva), Switzerland. Its primary stock listing is on the SIX Swiss Exchange (GIVN), and it trades in Swiss Francs (CHF).
History & Heritage	Swiss-founded. Established in 1895 in Zurich/Vernier by Leon and Xavier Givaudan. Its primary innovation hubs—including the Dübendorf R&D center near Zurich—remain anchored in Switzerland.
Operations & Employees	Global. With ~16,000+ employees operating across more than 160 locations worldwide, only a small fraction of the workforce is physically based in Switzerland.
Revenue & Sales	Nearly 100% Foreign. Virtually all revenue comes from international markets (Europe, North America, Asia-Pacific, and Latin America). Switzerland itself represents less than 2% of total sales.
Shareholders	International. While major Swiss institutions hold stock, large global institutional investors (such as US-based asset managers and private trusts) own significant stakes.

That was it on Givaudan. Right now one share is CHF 4’050,00. Reint Jelger